Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

“In November 2022, a study revealed that blood pressure drugs that stimulate type 2 and 4 angiotensin II receptors in the brain were associated with lower rates of dementia among new users of ...

Ozempic could cut the risk of dementia by half, a University of Oxford study has suggested. Scientists set out to establish the impact of the weight-loss jab on the brain in the first study of its ...

Blockbuster weight loss jabs relied on by millions of slimmers could slash the risk of developing dementia, two major studies have suggested. Semaglutide — the powerful ingredient behind Wegovy ...

New study suggests that Novo Nordisk’s Ozempic may lower dementia risk and nicotine use. Meanwhile, UnitedHealth Group’s cyberattack woes aren’t over yet.

Semaglutide, the main ingredient in Ozempic and Wegovy, improves type 2 diabetes, heart disease, smoking, and alcohol consumption, which all raise the risk of Alzheimer’s. Menu Newsletters Search ...

A study finds a drug known for weight loss may also help to reduce dementia. The study looked at semaglutide, the scientific name for Novo Nordisk's (NVO) (DK:NOVO.B) Ozempic, with the intent of ...

The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on the body, researchers say. The analysis, involving about two million ...